Novel therapeutics for patients with non-muscle-invasive bladder cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 6, 2009, Pages 807-813

  Svatek, Robert S ^a   Kamat, Ashish M ^a   Dinney, Colin P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apaziquone; Bladder cancer; Electromotive; Gene therapy; Photodynamic; Superficial; Therapeutics; Thermo chemotherapy

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; AMINOLEVULINIC ACID; APAZIQUONE; BCG VACCINE; DOCETAXEL; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; PACLITAXEL; ANTINEOPLASTIC AGENT;

APOPTOSIS; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CLINICAL TRIAL; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; HUMAN; HYPERTHERMIC THERAPY; MULTIPLE CYCLE TREATMENT; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC THERAPY; REVIEW; SIDE EFFECT; TRANSURETHRAL RESECTION; URINARY FREQUENCY; URINARY URGENCY; VIRAL GENE DELIVERY SYSTEM; BLADDER TUMOR; CANCER INVASION; DISEASE COURSE; GENE THERAPY; METHODOLOGY; PHOTOCHEMOTHERAPY; RISK FACTOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GENE THERAPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 68849114375     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.32     Document Type: Review

References (37)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466-465 (2006).
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18), 1315-1330 (2003).
3. Brassell SA, Kamat AM. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J. Natl Compr. Cane. Netw. 4(10), 1027-1036 (2006).
4. Herr HW. Transurethral resection and intravesical therapy of superficial bladder tumors. Urol. Clin. North Am. 18(3), 525-528 (1991).
5. Melekos MD, Chionis H, Pantazakos A et al. Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J. Urol. 149(4), 744-748 (1993).
6. Pagano F, Bassi P, Milani C et al. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol. 146(1), 32-35 (1991).
7. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168(5), 1964-1970 (2002).
8. Babjuk M, Oosterlinck W, Sylvester R et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54(2), 303-314 (2008).
9. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171(6 Pt 1), 2186-2190 (2004).
10. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol. 156(6), 1934-1940 (1996).
11. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 21(1B), 765-769 (2001).
12. Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol. Clin. North Am. 27(1), 125-135 (2000).
13. Campodonico F, Mattioli F, Manfredi V et al. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. Anticancer Res. 27(2), 1179-1183 (2007).
14. Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24(18), 2729-2734 (2006).
15. Dalbagni G, Russo P, Sheinfeld J et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol. 20(15), 3193-3198 (2002).
16. McKiernan JM, Masson P, Murphy AM et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J. Clin. Oncol. 24(19), 3075-3080 (2006).
17. Witjes JA, van der Heijden AG, Vriesema JL et al. Intravesical gemcitabine: a Phase 1 and pharmacokinetic study. Eur. Urol. 45(2), 182-186 (2004).
18. Witjes JA, Kolli PS. Apaziquone for non-muscle invasive bladder cancer: a critical review. Expert Opin. Investig. Drugs 17(7), 1085-1096 (2008).
19. van der Heijden AG, Moonen PM, Cornel EB et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J. Urol. 176(4 Pt 1), 1349-1353 (2006).
20. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 10(4), 947-959 (1999).
21. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66(4), 726-731 (2005).
22. Di Stasi SM, Vespasiani G, Giannantoni A et al. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res. 57(5), 875-880 (1997).
23. Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol. 170(3), 777-782 (2003).
24. Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7(1), 43-51 (2006).
25. Bochner BH. Intravesical bacillus Calmette-Guerin combined with electromotive mitomycin for high-risk superficial bladder cancer. Nat. Clin. Pract. Oncol. 3(9), 474-475 (2006).
26. Colombo R, Lev A, Da Pozzo LF et al. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J. Urol. 153(3 Pt 2), 959-963 (1995).
27. Herman TS, Teicher BA, Jochelson M et al. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int. J. Hyperthermia 4(2), 143-158 (1988).
28. Colombo R, Da Pozzo LF, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol. 21(23), 4270-4276 (2003).
29. van der Heijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur. Urol. 46(1), 65-71 (2004).
30. Bochner BH. Gene therapy in bladder cancer. Curr. Opin. Urol. 18(5), 519-523 (2008).
31. Fisher M, Benedict WF, Culter DL et al. Preliminary results of "a Phase I study with intravesical administration of adenoviral-mediated interferon-α for patients with BCG refractory transitional cell carcinoma of the bladder. Presented at: American Urological Association Meeting. IL, USA, 25-30 April 2009.
32. Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J. Urol. 167(1), 364-367 (2002).
33. Sidi AA, Ohana P, Benjamin S et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J. Urol. 180(6), 2379-2383 (2008).
34. Berger AP, Steiner H, Stenzl A et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61(2), 338-341 (2003).
35. Waidelich R, Beyer W, Knuchel R et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 61(2), 332-337 (2003).
36. Shackley DC, Briggs C, Gilhooley A et al. Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU Int. 89(7), 665-670 (2002).
37. Oosterlinck W, Lobel B, Jakse G et al. Guidelines on bladder cancer. Eur. Urol. 41(2), 105-112 (2002).